E³ - Advanced Course: Hybrid Imaging
E³ 1819 - Hybrid imaging in prostate cancer
Lectures
1
Chairperson's introduction
05:00Tara Barwick, London / UK
2
PET/MR and prostate cancer: when does it really matter?
23:00Matthias Eiber, Vaterstetten / DE
3
Theranostics in prostate cancer
23:00Amy Eccles, London / UK
4
Clinical cases: whole-body PSMA PET/CT incl. pitfalls
23:00Tara Barwick, London / UK
5
Panel discussion: Rockstar PSMA: what remains to be accomplished?
16:00Panel discussion: Rockstar PSMA: what remains to be accomplished?
5 min
Chairperson's introduction
Tara Barwick, London / United Kingdom
23 min
PET/MR and prostate cancer: when does it really matter?
Matthias Eiber, Vaterstetten / Germany
- To identify how PSMA PET/MRI improves the diagnostic accuracy for localisation of PCA, especially in patients with PIRADS 3, and the local staging with regard to SVI in comparison to mpMRI.
- To evaluate the improvement in the detection and characterisation of primary PCA with the simultaneous acquisition of PET images using PSMA and mp-MRI, which provides metabolic, structural, and functional information of PCA status in a single session of the whole body.
23 min
Theranostics in prostate cancer
Amy Eccles, London / United Kingdom
- To name different tracers used in the assessment of patients considered for molecular radiotherapy treatments for prostate cancer.
- To understand functional imaging in patient selection for molecular radiotherapy in prostate cancer.
- To understand functional imaging in response to molecular radiotherapy.
23 min
Clinical cases: whole-body PSMA PET/CT incl. pitfalls
Tara Barwick, London / United Kingdom
- To be familiar with the different PSMA PET radiotracers.
- To understand the strengths and weaknesses of PSMA imaging.
- To review clinical cases, focussing on potential pitfalls.
16 min
Panel discussion: Rockstar PSMA: what remains to be accomplished?